The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims

Sexually Transmitted Diseases

Volumn 33, Issue 10 SUPPL., 2006, Pages

  Gift, Thomas L ^a   Owens, Chantelle J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; DATA BASE; EPIDIDYMITIS; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHITIS; OUTPATIENT; PATIENT CARE; SEXUALLY TRANSMITTED DISEASE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AMBULATORY CARE; COSTS AND COST ANALYSIS; EPIDIDYMITIS; HUMANS; INSURANCE CLAIM REPORTING; MALE; ORCHITIS;

EID: 33749000569     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000235149.41948.fa     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 51:1-84.
2. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6-10.
3. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
4. Cates W Jr, Bolan G, Caine V, et al. Sexually transmitted diseases in America: How many cases and at what cost? In: Alexander LL, Cates JR, Herndon N, Ratcliffe JM, eds. Menlo Park, CA: Kaiser Family Foundation, 1998:1-27.
5. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002; 51(RR-6):1-80.
6. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: The case for screening. Prev Med 2003; 36:502-509.
7. Berger RE. Acute epididymitis. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999:847-858.
8. Idahl A, Boman J, Kumlin U, Olofsson JI. Demonstration of Chlamydia trachomatis IgG antibodies in the male partner of the infertile couple is correlated with a reduced likelihood of achieving pregnancy. Hum Reprod 2004; 19:1121-1126.
9. Washington AE, Johnson RE, Sanders LL Jr. Chlamydia trachomatis infections in the United States: What are they costing us? JAMA 1987; 257:2070-2072.
10. Institute of Medicine. Chlamydia. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy Press, 1999:149-158.
11. Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399.
12. Randolph AG, Washington AE. Screening for Chlamydia trachomatis in adolescent males: A cost-based decision analysis. Am J Public Health 1990; 80:545-550.
13. Ginocchio RHS, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003; 30:99-106.
14. Petitta A, Hart SM, Bailey EM. Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. Pharmacotherapy 1999; 19:648-654.
15. Mehta SD, Bishai D, Howell MR, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83-91.
16. Bureau of Labor Statistics. Consumer price index - all urban consumers; 2003 [cited March 1, 2004]. Available at: http://www.bls.gov/cpihome.htm. 2000.
17. International Classification of Diseases, 9th Revision, Clinical Modification, 5th ed. Salt Lake City: Medicode Publications, 1996.
18. National Drug Codes [database on the Internet]. Washington, DC: US Food and Drug Administration. [cited Sept 1, 2003]. Available at: http://www.fda.gov/cder/ndc/database/default.htm.
19. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; RR-1-51(RR-1):1-116.
20. 1999 MarketScan Research Databases User Guide and Database Dictionary. Ann Arbor: MEDSTAT Group, 2000.
21. Rein D, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000; 95:397-402.